Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | -0.40% | -.--% |
04:26pm | GSK Says Depemokimab Reduced Asthma Attacks in 2 Late-Stage Studies | MT |
02:03pm | GSK's Potential Blockbuster Asthma Drug Shows Promise in Latest Trial -- 2nd Update | DJ |
Sales 2024 * | 31.63B 40.19B 37.03B 3,163B | Sales 2025 * | 33.58B 42.68B 39.32B 3,358B | Capitalization | 72.39B 91.98B 84.74B 7,239B |
---|---|---|---|---|---|
Net income 2024 * | 5.54B 7.05B 6.49B 554B | Net income 2025 * | 6.49B 8.25B 7.6B 649B | EV / Sales 2024 * | 2.68 x |
Net Debt 2024 * | 12.29B 15.61B 14.38B 1,229B | Net Debt 2025 * | 9.07B 11.52B 10.62B 907B | EV / Sales 2025 * | 2.43 x |
P/E ratio 2024 * |
12.9
x | P/E ratio 2025 * |
11.1
x | Employees | - |
Yield 2024 * |
3.43% | Yield 2025 * |
3.56% | Free-Float | 94.54% |
Latest transcript on GlaxoSmithKline plc
Managers | Title | Age | Since |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 30/04/10 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 30/04/23 |
James Ford
CMP | Compliance Officer | - | 31/07/95 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 30/04/23 |
Jonathan Symonds
CHM | Chairman | 66 | 31/08/19 |
Hal Barron
BRD | Director/Board Member | 62 | 31/12/17 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.93% | 705B | |
+32.82% | 583B | |
-3.67% | 364B | |
+20.19% | 332B | |
+4.94% | 291B | |
+16.64% | 238B | |
-4.13% | 210B | |
+10.63% | 209B | |
+8.75% | 169B |
- Stock Market
- Equities
- GSK Stock
- GSK Stock